
Vyepti Market Report 2026
Epidemiology, Pipeline Analysis, Market Insights & Forecasts
Vyepti Market Overview
• The Vyepti market growth in the historic period has been driven by increasing prevalence of chronic migraine conditions, rising diagnosis rates of neurological disorders • Market expansion is supported by increasing development of next-generation monoclonal antibodies, rising demand for preventive migraine care • Growth Driver: Rising Migraine Prevalence Driving Growth In The Market • Market Trend: Innovative Intravenous (IV) Treatment For Migraine Relief • North America was the largest region in 2025.What Is Covered Under Vyepti Market?
Vyepti (eptinezumab-jjmr) is a medication used to prevent chronic migraines in adults. It is a monoclonal antibody that targets and inhibits calcitonin gene-related peptide (CGRP), a protein that transmits pain associated with migraines. Vyepti offers a treatment option for individuals suffering from chronic migraines, helping to reduce the frequency of migraine attacks and improve quality of life. The main types of indications for vyepti are chronic migraine, episodic migraine, and other neurological indications. Chronic migraine is a neurological condition marked by headaches occurring 15 or more days per month for at least three months, with significant impact on daily life. It is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies and cater to various end users including adult, and geriatric.
What Is The Vyepti Market Size and Share 2026?
The growth in the historic period can be attributed to increasing prevalence of chronic migraine conditions, rising diagnosis rates of neurological disorders, growing acceptance of biologic migraine therapies, expansion of specialty neurology clinics, improved access to advanced migraine treatments.What Is The Vyepti Market Growth Forecast?
The growth in the forecast period can be attributed to increasing development of next-generation monoclonal antibodies, rising demand for preventive migraine care, expansion of personalized neurology treatment approaches, growing investments in biologic drug pipelines, increasing focus on long-duration migraine therapies. Major trends in the forecast period include increasing adoption of cgrp-targeted migraine therapies, rising use of long-acting preventive migraine treatments, growing focus on biologic-based neurological drugs, expansion of hospital-based infusion therapies, enhanced emphasis on personalized migraine management.Global Vyepti Market Segmentation
1) By Indication: Chronic Migraine, Episodic Migraine, Other Neurological Indications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adult, GeriatricWhat Are The Drivers Of The Vyepti Market?
The increasing prevalence of migraines is expected to propel the growth of the vyepti market going forward. Migraines refer to severe headaches often accompanied by symptoms such as nausea, vomiting, and sensitivity to light or sound. The prevalence of migraines is attributed to a combination of genetic, environmental, and lifestyle factors, including hormonal changes, stress, sleep disturbances, and certain dietary triggers. Vyepti (eptinezumab) treats migraines by targeting and inhibiting the CGRP (calcitonin gene-related peptide) protein, which plays a key role in the development of migraine headaches, thus reducing the frequency and severity of migraines. For instance, in August 2025, according to The Migraine Trust, a UK-based charity organization, A&E attendance for migraine in England rose by 22% in 2023/2024 compared to the previous year. Therefore, the increasing prevalence of migraines is driving the growth of the vyepti industry. The increasing healthcare investment and access are expected to propel the growth of the vyepti market going forward. Healthcare investment and access is a funding effort to improve healthcare systems and ensure everyone can access affordable, timely, and quality care. Healthcare investment and access are increasing due to aging populations, global health crises, efforts to reduce health inequities, rising costs, and greater public awareness. Healthcare investment and access boost the VYPETI sector by enhancing service quality, fostering innovation, and creating growth opportunities through increased funding for research, broader access to advancements, and expanding demand. For instance, in May 2024, according to the Office of National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with a growth of 0.9% in 2022. Therefore, the increasing healthcare investment and access are driving the growth of the vyepti industry.Key Players In The Global Vyepti Market
Major companies operating in the vyepti market are H. Lundbeck A/S.Global Vyepti Market Trends and Insights
The key trend in the Vyepti market is the geographic expansion of advanced migraine-preventive therapies into major Asian regions, improving access for underserved patient populations. This trend reflects the growing focus on bringing biologic treatments to countries where preventive migraine options remain limited. For instance, in November 2025, H. Lundbeck A/S, a Denmark-based pharmaceutical company, had its new drug application for Vyepti (eptinezumab) accepted by Japan’s Ministry of Health, Labour and Welfare (MHLW), marking a significant step toward its launch across key Asian markets. Vyepti (eptinezumab) is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a key molecule involved in migraine attacks, and is designed for intravenous administration, offering rapid and sustained relief from migraine symptoms.Regional Insights
North America was the largest region in the vyepti market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.What Defines the Vyepti Market?
The vyepti market consists of sales of vyepti injection, IV infusion supplies, sterile accessories, and storage equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Vyepti Market Report 2026?
The vyepti market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vyepti industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Vyepti Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $ billion |
| Revenue Forecast In 2035 | $ billion |
| Growth Rate | No CAGR found from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Indication, Distribution Channel, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | H. Lundbeck A/S. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
